Physicochemical characterization of a novel graphene-based magnetic resonance imaging contrast agent

Shruti Kanakia1
Jimmy D Toussaint1
Sayan Mullick Chowdhury1
Gaurav Lalwani1
Tanuf Tembulkar1
Terry Button1,2
Kenneth R Shroyer3
William Moore2
Balaji Sitharaman1

1Department of Biomedical Engineering, 2Department of Radiology, 3Department of Pathology, Stony Brook University, Stony Brook, NY, USA

Correspondence: Balaji Sitharaman
Department of Biomedical Engineering, Bioengineering Building, Rm #115, Stony Brook University, Stony Brook, NY 11794-5281, USA
Tel +1 631 632 1810
Email balaji.sitharaman@stonybrook.edu

Abstract: We report the synthesis and characterization of a novel carbon nanostructure-based magnetic resonance imaging contrast agent (MRI CA); graphene nanoplatelets intercalated with manganese (Mn2+) ions, functionalized with dextran (GNP-Dex); and the in vitro assessment of its essential preclinical physicochemical properties: osmolality, viscosity, partition coefficient, protein binding, thermostability, histamine release, and relaxivity. The results indicate that, at concentrations between 0.1 and 100.0 mg/mL, the GNP-Dex formulations are hydrophilic, highly soluble, and stable in deionized water, as well as iso-osmolar (upon addition of mannitol) and isoviscous to blood. At potential steady-state equilibrium concentrations in blood (0.1–10.0 mg/mL), the thermostability, protein-binding, and histamine-release studies indicate that the GNP-Dex formulations are thermally stable (with no Mn2+ ion dissociation), do not allow non-specific protein adsorption, and elicit negligible allergic response. The r1 relaxivity of GNP-Dex was 92 mM−1 s−1 (per-Mn2+ ion, 22 MHz proton Larmor frequency); ~20- to 30-fold greater than that of clinical gadolinium (Gd3+) - and Mn2+-based MRI CAs. The results open avenues for preclinical in vivo safety and efficacy studies with GNP-Dex toward its development as a clinical MRI CA.

Keywords: manganese, dextran, preclinical, physicochemical properties, relaxivity, graphene, magnetic resonance imaging, contrast agent

Introduction

Magnetic resonance imaging (MRI) is a central whole-body imaging technique used to visualize anatomical structures in biomedical research and clinical medicine. The application of MRI contrast agents (CAs) has enabled improvements in diagnostic confidence as a result of better contrast achieved by shortening the characteristic $T_1$ or $T_2$ relaxation time of in vivo water protons. Since the 1980s, researchers have developed a variety of clinical MRI CAs that are complexes of paramagnetic metal ions such as gadolinium (Gd3+), manganese (Mn2+), or iron (Fe2+, Fe3+). The Gd3+ chelate-based $T_1$ MRI CAs currently dominate the market (>95% market share) and, in the USA, approximately 45% of the 28 million clinical MRI procedures use MRI CAs. Recently, the US Food and Drug Administration (FDA) restricted the clinical use of Gd3+ chelate-based $T_1$ MRI CAs for patients affected by renal failure. Thus, there is a need for a $T_1$ MRI CA that is safer and more efficacious than clinical Gd3+ chelate-based agents, and employing Mn2+ ions have been proposed as possible alternatives.

The two-dimensional carbon nanostructure graphene has attracted a great deal of attention for biomedical applications owing to its unique physicochemical properties. Recently, we thoroughly and systematically investigated the structural, chemical, magnetic, and relaxometric properties of a novel Mn2+ intercalated graphene nanostructure known as “graphene oxide nanoplatelets.” Our results indicate that these nanoparticles...
are disc-shaped with diameters ~20–40 nm and thickness ~2–3 nm, paramagnetic, and their suspensions (0.1–1.0 mg/mL concentrations) in biocompatible Pluronic® F-127 (1 wt%; # P-3000MP, Life Technologies, Carlsbad, CA, USA) solutions at clinically relevant magnetic fields (eg, 1.5 Tesla) show an order of magnitude or greater $r_1$ relaxivity\(^7\) (relaxivity $r_1$ or $r_2$ is a measure of the efficacy of an MRI CA, and is defined as the change in relaxation rate [inverse of $T_1$ or $T_2$ relaxation time] per unit concentration of the MRI CA)\(^1\) than clinical Gd\(^{3+}\)-based (eg, Magnevist™, Bayer Schering Pharma, Berlin-Wedding, Germany) or Mn\(^{2+}\) chelate-based (eg, Teslascan [GE Healthcare, Little Chalfont, UK]) MRI CAs.\(^8\) The high relaxivity may allow the development of MRI CAs that show the same clinical MRI performance at substantially lower dosages, and could also allow their development for advanced applications such as MRI CAs for extended-residence-intravascular, tissue (organ)-specific, and molecular imaging. However, to translate this promising MRI CA into the clinic, the hydrophobic graphene nanoplatelets need to be water solubilized at much higher concentrations (in the range of tens of mg/mL) with suitable biocompatible moieties, and their stability needs to be ensured at these high concentrations in biological media or blood. Additionally, in vitro and in vivo preclinical assessment of the water-soluble graphene oxide nanoplatelet formulation’s physicochemical characteristics, toxicity, and efficacy is necessary according to the US FDA guidelines.\(^9\)-\(^11\)

As a first step in their preclinical development, we have synthesized and characterized highly water-soluble Mn\(^{2+}\) intercalated graphene nanoplatelets non-covalently functionalized with the natural polymer dextran (hereafter called GNP-Dex), and have assessed eight key in vitro physicochemical properties (osmolality, viscosity, partition coefficient, protein binding, thermostability, histamine release, relaxivity, and in vitro phantom MRI) required by the US FDA during an investigational new drug application of MRI CAs for approval to perform first-in-human trials.\(^9\)-\(^11\)

**Methods**

**Synthesis of GNP-Dex**

The Mn\(^{2+}\) intercalated graphene oxide nanoplatelets (GNPs) were prepared according to the previously described method.\(^7\) The GNPs were non-covalently functionalized with dextran (technical grade, MW 10,000 Da; Pharmacosmos, Høbaek, Denmark) to synthesize GNP-Dex as follows. GNPs and dextran were mixed in distilled deionized (DDI) water at a 1:10 weight ratio, and bath sonicated for 30 minutes followed by the addition of ammonium hydroxide (NH\(_4\)OH). The mixture was then stirred at 95°C for 3 hours. Next, the particles were centrifuged at 1,000 rpm for 15 minutes, and the supernatant was carefully transferred into Falcon™ tubes (BD Biosciences, San Jose, CA, USA) to obtain water-soluble GNP-Dex. The supernatant was lyophilized and the solid powder resuspended in DDI water at desired concentrations. The Mn\(^{2+}\) ion concentration in GNP-Dex was measured by inductively coupled plasma mass spectrometry (ICP-MS) and Mn\(^{2+}\) weight percent in the GNP-Dex was measured to be 0.064%. Mannitol (M8129, Sigma-Aldrich, St Louis, MO, USA) was added to the GNP-Dex solutions to regulate the osmolality within the range of blood (290–320 mOsm/kg).

**Characterization of the GNP-Dex**

**Transmission electron microscopy**

Transmission electron microscopy (TEM) was performed using a JEOL JEM-2100F high-resolution Transmission Electron Microscope (Tokyo, Japan) at the Center for Functional Nanomaterials, Brookhaven National Laboratory, Upton, New York, USA. The GNP-Dex solutions (1 mg/mL) were sonicated for 1 minute then centrifuged at 5,000 rpm for 5 minutes. A drop (10 µL) of the resulting supernatant was placed on TEM grids (300 mesh size, holey lacey carbon, Ted Pella, Inc, Redding, CA, USA), dried, and imaged at 200 kV accelerating voltage.

**Atomic force microscopy**

After sonication and centrifugation (5,000 rpm, 5 minutes), the GNP-Dex solutions were spin coated at 3,000 rpm for 5 minutes on freshly cleaved silicon wafers (Ted Pella, Inc.). A V-shaped cantilever of frequency $f_c = 145–230$ kHz, $L = 225 \mu$m, $W = 40 \mu$m, tip radius <10 nm, and spring constant $k = 20–95$ N/m (ACL-10, Applied NanoStructures, Inc., Mountain View, CA, USA) were used. Samples were imaged using a NanoSurf® EasyScan 2 FlexAFM (NanoScience Instruments, Inc., Phoenix, AZ, USA) operating in tapping mode under ambient conditions (50% relative humidity, 25°C).

**Thermogravimetric analysis**

Thermogravimetric analysis (TGA) was performed on GNPs, dextran (MW 10,000 Da), and GNP-Dex using a PerkinElmer Diamond 500 (Waltham, MA, USA) instrument at Brookhaven National Laboratory. The samples were heated from 50°C to 700°C at a heating rate of 10°C/min under an airflow of 100 mL/min.

**Elemental analysis**

The GNP-Dex samples were analyzed by ICP-MS (Finnigan™ ELEMENT 2, Thermo Fisher Scientific,
Waltham, MA, USA) to determine the concentration of Mn$^{2+}$ ions. For the ICP analysis, liquid GNP-Dex samples (of known concentration) were treated with concentrated nitric acid (HNO$_3$) and carefully heated to obtain a solid residue. Next, this residue was treated with 30% H$_2$O$_2$ and heated again to remove any carbonaceous material. The remaining non-carbonaceous solid residue was dissolved in 2% HNO$_3$ and analyzed by ICP-MS.

**Physicochemical properties assessment**

**Osmolality**

The osmolality of 300 µL GNP-Dex solutions at concentrations 100.0, 50.0, 20.0, 10.0, and 0.4 mg/mL were measured using a freezing point depression osmometer (model no 3D3, Advanced Instruments, Norwood, MA, USA). Mannitol, an osmotic diuretic agent, was added to adjust their osmolality to obtain values similar to that of blood.

**Viscosity**

The viscosity of the GNP-Dex formulations at concentrations 100.0, 50.0, 20.0, 10.0, and 0.4 mg/mL with sample volume of 700 µL were measured using a rotating spindle viscometer (DV-I Prime Digital Viscometer, Brookfield Engineering, Middleboro, MA, USA) at 37°C.

**Partition coefficient**

The partition coefficient was measured using the well-established flask-shaking method.$^{12}$ Briefly, 100 µL of 20 mg/mL GNP-Dex solution was added to a Falcon tube that contained 1-octanol/DDI water mixture (1 mL each phase, n = 3). The two phases were thoroughly mixed by vigorously shaking the Falcon tube for ~30 seconds. The Falcon tube was then kept still for 120 minutes at room temperature to allow the two phases to separate. Aliquots of the aqueous phase were removed after 145, 205, and 255 minutes. The concentration of the nanoparticles in aqueous phase was determined by ultraviolet–visible (UV-Vis) spectrophotometry using an Evolution 300 UV-Vis Spectrophotometer (Thermo Fisher Scientific) at 254 nm wavelength. The partition coefficient ($P_{ow}$) was calculated as logarithm of the ratio of the GNP-Dex concentrations in octanol to water phase as follows: \[ \log P_{ow} = \log ([\text{nanoparticles}] \text{ octanol}/[\text{nanoparticles}] \text{ DDI water}). \]

**Protein binding**

Protein binding was studied using an MB 74-1610 Micro-Equilibrium Dialyzer™ (Harvard Apparatus, Holliston, MA, USA). The protein human serum albumin (HSA) and GNP-Dex (500 µL each) at concentrations of 0.1, 1.0, and 10.0 mg/mL (n = 3 per concentration) were pipetted into two separate chambers of the dialyzer. The two chambers were partitioned with a cellulose acetate membrane (100 kDa, molecular weight cut off). The dialysis chamber was allowed to equilibrate at 37°C in an incubator for 24 hours. The samples from each chamber were pipetted out at the end of 24 hours. The equilibrated concentration of HSA in both the compartments was quantified by colorimetry using bicinchoninic acid (BCA) assay (BCA Pierce® BCA Protein Assay Kit, Thermo Fisher Scientific) at 562 nm, using a plate reader (Infinite® M200, Tecan Group Ltd, Morrisville, NC, USA).

**Thermostability**

The thermal stability of the intercalated Mn$^{2+}$ ions in the GNP-Dex formulations was characterized at physiological temperature (37°C), and compared with the concentration of free Mn$^{2+}$ ions in the formulation at room temperature (25°C). One milliliter of each of the 20, 50, and 100 mg/mL concentration GNP-Dex solutions was incubated at 25°C and 37°C for 24 hours, followed by centrifugation at 7,000 rpm for 10 minutes. The supernatants were analyzed for the presence of free Mn$^{2+}$ ions using sodium bismuthate (NaBiO$_3$) assay. A standard optical absorbance versus concentration curve was prepared with known concentrations of potassium permanganate (KMnO$_4$), which has distinctive pink color, using UV-Vis spectrophotometry at 578 nm. This standard curve was used to obtain the unknown concentration of permanganate (MnO$_4^-$) ions produced by the NaBiO$_3$ reaction by measuring the absorbance values at 578 nm. This value allowed the determination of the concentration of free Mn$^{2+}$ ions in the supernatant of the GNP-Dex formulations.

**Histamine release**

Histamine release was measured using a histamine enzyme-linked immunosorbent assay kit (#IB89128, Immuno-Biological Laboratories Inc, Minneapolis, MN, USA) on heparinized whole human blood (10761 WB-SH-FF, BioChemed Services, Inc, Winchester, VA, USA). The assay was performed according to the protocol provided by the supplier. GNP-Dex solutions at concentrations of 0.1, 1.0, and 10.0 mg/mL (200 µL) and control (200 µL) (provided with the kit) were first incubated with blood (200 µL) at 37°C for 60 minutes. The samples were centrifuged at 700x g for 10 minutes and 50 µL of supernatant from each sample was transferred into a reaction plate (provided with the kit) for acylation. In the reaction plate, the samples were incubated with 25 µL of acylation reagent (to convert any released histamine into N-acylhistamine) for 45 minutes.
at room temperature. Acylated controls and test solutions (GNP-Dex) (25 μL each) were incubated with histamine antiserum (100 μL) in histamine microtiter strips (provided with the kit, with solid-phase histamine bound to the wells) overnight at 4°C. The following day, after discarding the contents of the well, and rinsing the well with wash buffer (provided with the kit), the wells were treated with 100 μL of enzyme conjugate at room temperature for 30 minutes. Next, the contents of the wells were again discarded, and each well was rinsed with wash buffer. A total of 100 μL of stop solution (provided with the kit) was added in the wells, and the absorbance readings were taken at 450 nm with reference wavelength of 630 nm, using an enzyme-linked immunosorbent assay reader (Infinite M200, Tecan Group Ltd).

Relaxivity
The longitudinal ($T_1$) relaxation time of 250 μL GNP-Dex solutions at different concentrations (0.4, 10.0, 20.0, 50.0, and 100.0 mg/mL) was measured at room temperature using a relaxometer (iSpin-NMRSM; SpinCore Technologies, Inc., Gainesville, FL, USA) with a 0.47 T (21.42 MHz resonance frequency) magnetic field. Samples were placed in a clean 8 mm diameter nuclear magnetic resonance tube (Norell, Inc., Landsiville, NJ, USA). The $T_1$ measurements were made using an inversion recovery sequence, where inversion time was varied in 12 steps between 0.5 and 5,000.0 milliseconds. The plot of relaxation rate (1/$T_1$, y-axis) versus concentration (mM of Mn$^{2+}$, x-axis) was fit to a linear least-square regression line. The slope of this line provided the relaxivity $r_1$ value of the GNP-Dex. As described earlier, the Mn$^{2+}$ ion concentration was measured by ICP-MS.

Magnetic resonance (MR) phantom imaging
The MRI phantoms were prepared at GNP-Dex concentrations of 7.800, 3.900, 1.900, 0.780, 0.390, and 0.015 mg/mL in DDI water. Dextran solution (4.68 mg/mL) and DDI water were used as controls. $T_1$-weighted MRI using spin-echo sequence was performed using a 1.5 T clinical GE Healthcare scanner (carried out at Stony Brook University Hospital, Stony Brook, NY, USA). The slice thickness was set to 3 mm, in plane resolution 2.56 pixel/mm, acquisition time 115.2 seconds and number of averages was 1. The echo time (TE) and repetition time (TR) were set at 10 and 800 milliseconds, respectively. The field of view was set at 100 × 100 mm and the flip angle was 90°.

Results and discussion
The overall objectives of the studies reported were to synthesize and characterize water-soluble graphene nanoplatelet formulations that are stable at high concentrations in biological media and blood, and to characterize key in vitro physicochemical properties of the water-soluble GNPs based on US FDA guidelines and investigations performed on other MRI CAs during their translation into clinic.9–13 The hydrophobic GNPs were non-covalently functionalized with dextran, since previous reports show that it imparts good water solubility to graphene nanoparticles.14 Additionally, dextran has been used for a number of biomedical applications, including the development of the experimental Gd$^{3+}$-based15 and clinical iron oxide-based MRI CAs.16 Furthermore, dextran is non-fouling,17 could prevent nonspecific interactions and may prolong blood circulation half-life in vivo15 – essential features for potential advanced MRI applications such as blood pool imaging. Concentrations up to 100 mg/mL were used in the studies since future in vivo preclinical safety and efficacy studies would require the administration of GNP-Dex at high dosages (up to possibly 500 mg/kg body weight of the animal) to determine the lethal and therapeutic dosages. Our estimates (see Calculation of the dose in the Supplementary materials section) indicate that to achieve these in vivo dosages, stock nanoparticle solutions with concentration as high as 100 mg/mL will be needed. For some physicochemical characterization studies, concentrations between 0.1 and 10.0 mg/mL were used, which correspond to their steady-state equilibrium concentration in the blood (volume = 12–13 mL) of a rodent (weight –200 g) after the first pass, if the GNP-Dex formulations are injected intravenously at dosages between 1 and 500 mg/kg.

Figure 1 shows the TEM and atomic force microscopy (AFM) images of GNP-Dex, and provides the formulation’s structural and morphological information. The low- and high-resolution TEM images (Figure 1A and B) show that GNP-Dex are disc-shaped nanoparticles with a coil-like dextran structure uniformly coating the GNPs. The size of the GNP-Dex complex, determined by the analysis of the TEM and the AFM images (Figure 1C and D) was 100–120 nm. Further, the thickness of the GNP-Dex complex determined by AFM was 3–4 nm.

Figure 2 shows the TGA spectrum of the GNP-Dex formulation. Also included for comparison are TGA spectra of GNPs and dextran. The TGA spectra of the GNPs show a weight loss of 10% between 10°C and 150°C due to the loss of adsorbed moisture. The weight loss of 20% between 150°C and 200°C can be attributed to the pyrolysis of carboxyl or hydroxyl groups.18 The dextran curve exhibits a 80%–90% weight loss between 300°C and 350°C, which is the characteristic decomposition temperature of...
Comparing the thermogram of GNP-Dex with those of GNPs and dextran gives information about the formulation’s composition and chemical modifications. The thermogram of GNP-Dex shows 10% weight loss at 100°C due to loss of moisture. The 10% weight loss of GNP-Dex in the region between 150°C and 200°C is due to loss of the labile oxygen-containing groups. This value is lower than the % weight loss observed for the GNPs in this region, which suggests partial reduction of the GNPs during the functionalization with dextran. The 40% weight loss between 250°C and 350°C indicates the presence of the dextran, and implies that GNP-Dex contains dextran at 40% by weight.

Figure 3 shows digital photographs of GNP-Dex solutions at 0.4, 10.0, 20.0, 50.0, and 100.0 mg/mL concentrations (containing mannitol) at 0, 2, 4, and 24 hours after preparation of the solutions. As is evident in the images, the solutions at all concentrations were stable for up to 4 hours. At 24 hours, the GNP-Dex solution at a concentration of 100 mg/mL separated out. However, this could be easily and uniformly re-dispersed by shaking it gently. An important consideration during in vivo administration of GNP-Dex...
formulations is that they should remain stable long enough for the dose to be poured out and injected. In general, settling is considered a significant issue if the solute cannot be easily and uniformly re-dispersed. The results indicate that, provided the GNP-Dex formulations at various concentrations are prepared fresh and administered immediately, or solutions (especially at very high concentrations) kept for an extended period of time are gently shaken, they are suitable as stock solutions for in vivo administration. The higher stability of the formulations in water can be attributed to the uniform coating of dextran on GNPs, which counteracts the hydrophobic forces exerted by the GNPs that can lead to aggregation.

To the best of our knowledge, this is the highest level of solubility that has been achieved for any water-solubilized graphene nanoparticle. An MRI CA needs to exhibit excellent solubility even at high concentrations to achieve the dose required for bolus injection (the clinical dose of a Gd$^{3+}$ chelate-based MRI CA can be between 1 and 100 mg/kg<sup>21</sup>). Additionally, an important consideration is that the water-solubilizing moieties need to be biocompatible. Different covalent and non-covalent functionalization approaches have been employed to water-solubilize graphene nanoparticles. Graphene nanoparticles have been covalently functionalized with carboxylic acid, hydroxyl, poly-L-lysine, and non-covalently functionalized with synthetic polymer polyethylene glycol<sup>6</sup> or Pluronic F-127.<sup>7</sup> The maximum solubility reported for these functionalization approaches has been between 1 and 2 mg/mL. Recently, graphene nanoparticles have been covalently conjugated with the natural polymer dextran with a maximum water solubility of 1 mg/mL.<sup>14,24,25</sup> At the concentration of 1 mg/mL, the volume needed to be injected for in vivo small animal safety studies to achieve the above dosages (1–100 mg/kg) would be up to 1.56%–156.25% of the total blood volume (estimated based on a 200 g rat with total blood volume of ~12.8 mL; see Calculation of the dose in the Supplementary materials section) or 1.4%–140.0% of the total blood volume (5 L of an adult human weighing 70 kg; see the Supplementary materials section), which is not feasible at higher doses. The GNP-Dex formulations not only show substantially greater solubility than the other approaches but also stability in physiologically relevant fluids. Additionally, at high concentrations (eg, 50–100 mg/mL), GNP-Dex can be injected at ~4%–8% of the rat blood volume to achieve bolus dosages between 50 and 500 mg/kg, which is feasible.

Tables 1–4 show the results of assessments of the key physicochemical properties, osmolality, viscosity, partition coefficient, protein binding, histamine release, and relaxivity. Osmolality of an MRI CA is an important property that depends on the solute concentration. Adverse effects of contrast media with low or high osmolality (compared with blood osmolality) include changes in the circulatory system such as vasodilation, vasoconstriction, crenation of red blood cells, and release of vasopressin.<sup>9,26</sup> Clinically, these changes manifest as sensations of warmth, heat, and pain at

![Figure 2 Representative thermogravimetric analysis (TGA) curve of graphene nanoplatelets, dextran, and graphene nanoplatelets intercalated with manganese (Mn$^{2+}$) ions, functionalized with dextran (GNP-Dex).](image)

![Figure 3 Digital images of vials containing graphene nanoplatelets intercalated with manganese (Mn$^{2+}$) ions, functionalized with dextran (GNP-Dex) in water (with mannitol) at 100.0, 50.0, 20.0, 10.0, 0.4 mg/mL concentrations at (A) 0 hour (h), (B) 2 hours, (C) 4 hours, and (D) 24 hours after preparing the solutions.](image)
Table 1 Osmolality of graphene nanoplatelets intercalated with manganese (Mn²⁺) ions, functionalized with dextran (GNP-Dex) in distilled deionized water before and after the addition of mannitol

| Concentration (mg/mL) | Osmolality (mOsm/kg) before addition of mannitol (mean ± SD) | Osmolality (mOsm/kg) after addition of mannitol (mean ± SD) |
|-----------------------|-------------------------------------------------------------|-------------------------------------------------------------|
| 100.0                 | 33.0 ± 0.5                                                  | 306.7 ± 1.5                                                 |
| 50.0                  | 17.0 ± 0.3                                                  | 296 ± 0.0                                                   |
| 20.0                  | 5.0 ± 0.2                                                   | 297.7 ± 0.6                                                 |
| 10.0                  | 5.0 ± 0.1                                                   | 289.7 ± 1.5                                                 |
| 0.4                   | 3.0 ± 0.0                                                   | 303 ± 0.0                                                   |

Abbreviation: SD, standard deviation.

Table 2 Viscosity of graphene nanoplatelets intercalated with manganese (Mn²⁺) ions, functionalized with dextran (GNP-Dex) at different concentrations at 37°C

| Concentration (mg/mL) | 100 rpm (cP) | 50 rpm (cP) | 20 rpm (cP) |
|-----------------------|--------------|-------------|-------------|
| 100.0                 | ND           | 2.45        | 4.46        |
| 50.0                  | 2.37         | 3.68        | 2.82        |
| 20.0                  | 1.35         | 1.39        | 1.69        |
| 10.0                  | 1.60         | 2.10        | ND          |
| 0.4                   | 2.30         | 3.80        | ND          |

Abbreviation: ND, not determined.

Table 3 Physicochemical properties of graphene nanoplatelets intercalated with manganese (Mn²⁺) ions, functionalized with dextran (GNP-Dex)

| Parameter          | Results                      | Condition   |
|--------------------|------------------------------|-------------|
| Partition coefficient (log P<sub>ow</sub>) | <LOD (0.001 mg/mL) | 20 mg/mL at 25°C |
| Protein binding    | 0.1, 1.0, 10.0 mg/mL at 37°C |
| Released free Mn²⁺ ions | <LOD (0.01 µM) | 20.0, 50.0, |
| Histamine release  | <negative control | 100.0 mg/mL at 37°C |

Abbreviation: LOD, limit of detection.

The viscosity of MRI CAs depends on their chemical structure, concentration, and temperature. The viscosity of the GNP-Dex solutions at concentrations between 0.4 and 100.0 mg/mL at 37°C is shown in Table 2. The viscosity values at all concentrations were less than or within the range of blood viscosity (between 3 and 4 cP at 37°C). The viscosity of the GNP-Dex solutions was also dependent on shear rate at all concentrations, which suggests that GNP-Dex solution at these concentrations behaves as a non-Newtonian fluid, similar to whole blood. The viscosities of the MRI CA solutions affect their rate of injection and in vivo flow characteristics.

MRI CAs with viscosity values higher than that of blood typically cannot be injected intravenously as a bolus. They need to be injected at a slower rate. Higher viscosity MRI CAs have been shown to cause deleterious effects on renal perfusion and renal output. However, these effects can be mitigated by warming up the MRI CA prior to its in vivo administration to lower its viscosity. Studies show that MRI CAs with high viscosities (greater than that of blood) affect the intrinsic and extrinsic coagulation cascade pathways, platelet function and vascular endothelial function to a certain extent, while low-viscosity MRI CAs (with viscosities lower than that of blood) do not substantially affect these hemodynamic parameters.

The partition coefficient (P<sub>ow</sub>) of an MRI CA provides a measure of its hydrophilicity and hydrophobicity. In turn, these properties affect their in vivo biodistribution profile. The partition coefficient of GNP-Dex at concentrations 0.1, 1.0, and 10.0 mg/mL was calculated to be −0.18 (Table 3). This value is comparable to the values reported for clinical MRI CAs developed as extravascular agents (Table 5). Visual analysis also showed that the majority of the GNP-Dex separated into the aqueous phase or stayed at the aqueous–octanol interface and could not be detected in the octanol phase. No UV-Vis spectra

Table 4 T<sub>1</sub> (relaxation time) values of graphene nanoplatelets intercalated with manganese (Mn²⁺) ions, functionalized with dextran solutions and distilled deionized (DDI) water at different concentration and corresponding Mn²⁺ ion concentration

| Concentration (mg/mL) | T<sub>1</sub> time (ms) (mean ± SD) | Mn²⁺ concentration (mM) (mean ± SD) |
|-----------------------|------------------------------------|-------------------------------------|
| 100.0                 | 10.51 ± 0.27                       | 1.038                               |
| 50.0                  | 24.28 ± 1.34                       | 0.273                               |
| 20.0                  | 67.64 ± 0.42                       | 0.271                               |
| 10.0                  | 108.27 ± 1.94                      | 0.138                               |
| 0.4                   | 1,993.86 ± 227.38                  | 0.006                               |
| DDI water             | 5,672.92 ± 282.45                  | 0.000                               |

Abbreviation: SD, standard deviation.
Comparison of the physicochemical properties of graphene nanoplatelets intercalated with manganese (Mn$^{2+}$) ions, functionalized with dextran (GNP-Dex) with US Food and Drug Administration (FDA)-approved magnetic resonance imaging contrast agent (MRI CA)

| US FDA-approved MRI CA | Osmolality (mOsm/kg of water) | Viscosity (cP) at 37°C | Partition coefficient (log P<sub>oct</sub>) | Protein binding | Relaxivity (r<sub>1</sub>) mM⁻¹s⁻¹ at 0.47 T<sub>0</sub> |
|------------------------|-------------------------------|------------------------|---------------------------------------------|-----------------|---------------------------------------------|
| ProHance<sup>41</sup>   | 630                           | 1.3                    | −3.6800                                     | None            | 3.1                                         |
| MultiHance<sup>42,43</sup> | 1,970                         | 5.3                    | 0.0016                                      | <5%             | 4.2                                         |
| Magnevist<sup>44</sup>  | 1,960                         | 2.9                    | −5.4000                                     | None            | 3.4                                         |
| Omniscan<sup>TM45</sup> | 789                           | 1.4                    | −2.1000                                     | None            | 3.5                                         |
| Teslascan<sup>®42</sup> | 290                           | 0.7                    | −5.6200                                     | Fodipir chelate (negligible), free Mn$^{2+}$ ions (27%) | 1.5                                         |
| Optimark<sup>TM45</sup> | 1,110                         | 2.0                    | −8.2200                                     | None            | 4.2                                         |
| GNP-Dex                | 290                           | 2.4                    | −0.1800                                     | None            | 92                                          |

Notes: ProHance, Bracco Diagnostics Inc. Princeton, NJ, USA; MultiHance<sup>®</sup>, Bracco Diagnostics Inc.; Magnevist<sup>®</sup>, Bayer Schering Pharma, Berlin-Wedding, Germany; Omniscan<sup>TM</sup>, GE Healthcare, Little Chalfont, UK; Teslascan, GE Healthcare; Optimark<sup>TM</sup>, Mallinckrodt Inc., St Louis, MO, USA.

of the GNP-Dex in octanol phase could be obtained, indicating that the nanoparticles, if present, were below the detection limit of the instrument. The results indicate that most of the GNP-Dex nanoparticles were hydrophilic, and preferentially accumulate in the aqueous phase, and a small fraction were amphiphilic, accumulating at the water–octanol interface.

The propensity of MRI CAs to bind to protein could affect their targeting capability, pharmacokinetics, and relaxivity.<sup>9,31</sup> Equilibrium dialysis of an MRI CA with the protein HSA followed by BCA protein assay is one of the most widely-accepted methods for studying protein–drug interaction.<sup>32,33</sup> The results (Table S1) of the protein binding, summarized in Table 4, show that HSA protein was not bound to the GNP-Dex formulations. The lack of protein binding onto GNP-Dex can be attributed to the non-fouling property of dextran,<sup>11</sup> and suggests that it could prevent nonspecific interactions.

Thermal stability of the intercalated Mn$^{2+}$ ions is a key physiochemical property. It was important to determine if the intercalated Mn$^{2+}$ ions dissociate from the GNP-Dex nanoparticles and were present as free Mn$^{2+}$ ions under physiological temperatures. The Mn$^{2+}$ ion, a natural cellular constituent, functions as a regulatory cofactor for enzymes and receptors.<sup>2</sup> The normal daily dietary requirement for manganese is 2.7–7.0 mg,<sup>34</sup> and the normal serum level is 0.1 µM.<sup>35</sup> However, prolonged exposure to high concentrations of Mn$^{2+}$ ions has been reported to be toxic, and results in “manganism,” a Parkinson-like neurological disorder, and cardiac dysfunction.<sup>2,36</sup> Therefore, it was critical to investigate whether the intercalated Mn$^{2+}$ ions, at the physiological temperature of 37°C, dissociate from GNP-Dex nanoparticles. The thermal stability experiments (Table S2 and summarized in Table 4) with GNP-Dex solutions, for 3 or 24 hours, at 20, 50, and 100 mg/mL concentrations, show no presence of free Mn$^{2+}$ ions (limit of detection [LOD] = 0.01 µM) at 37°C. The results indicate that Mn$^{2+}$ ions present in the GNP-Dex formulation are stable at least short-term (24 hours) at simulated physiological temperature. Typically, clinical first pass or blood pool CAs have been reported to have average blood half-lives of 1.5 hours, and >95% of the CA is excreted in 24 hours.<sup>37</sup> Thus, taken together with this information, the reported results suggest that provided the in vivo blood half-life and the elimination rate of the GNP-Dex formulations are similar, the intercalated Mn$^{2+}$ ions should be stable within the graphene nanoplatelets in vivo. However, the long-term (>24 hours) in vitro and in vivo thermal stability of these formulations still needs to be determined before a firm conclusion can be drawn.

It is well documented that MRI CAs can evoke adverse allergic reactions with symptoms that can include urticaria or hives-like inflammation as well as swelling and reddening of the tissues, watery eyes, runny nose, migraine headaches, nausea, vomiting, laryngospasm, and bronchospasm.<sup>38–40</sup> Histamine, a naturally occurring biomolecule found in vivo, is released as a response to allergic reactions<sup>40</sup> and is considered a good marker to evaluate the propensity of an MRI CA to elicit an allergic response. Our results show no significant release of histamine at GNP-Dex concentrations of 0.1, 1.0, and 10.0 mg/mL compared with the control (Table S3). These results are encouraging since histamine can also stimulate fibroblast proliferation and collagen production, and can play an important role in skin fibrosis – a major symptom associated with nephrogenic systemic fibrosis.<sup>40</sup> Studies on Gd$^{3+}$- and Mn$^{2+}$-chelate MRI CAs indicate that, at physiologically relevant plasma concentrations (0.1–10.0 mM), they do not exhibit a propensity to release histamine. At higher dosages (50–150 mM), Gd$^{3+}$-chelate complexes have been shown to release histamine in vitro.<sup>40</sup>

Relaxivity is an important measure of efficacy for <i>T</i><sub>1</sub>-MRI CAs.<sup>1</sup> Our previous results show that the <i>r</i><sub>1</sub>/<i>r</i><sub>2</sub> ratio...
for water-solubilized GNP solutions is 2.2, which is in the range reported for Mn\(^{2+}\) or Gd\(^{3+}\)-chelate complexes \((r_1/r_2, -1.0 \text{ to } 2.5)\) \(T_2\) MRI CAs.\(^7,8\) The ratio is also lower than the iron oxide-functionalized graphene nanoparticles \((r_1/r_2, -10)\) \(T_2\) MRI CAs.\(^7\) Thus, the GNP-Dex formulations would be more suitable as \(T_1\) MRI CA. Table 4 shows \(T_1\) relaxation time at 0.47 T (21.42 MHz proton Larmor frequency) at different doses of GNP-Dex. Also included are the Mn\(^{2+}\) ion concentrations (in \(\mu M\)) for each GNP-Dex dose. The relaxivity value calculated from the plot (Figure 4A) of \(1/T_1\) versus Mn\(^{2+}\) ion concentration is 92.2 mM\(^{-1}\)s\(^{-1}\). MR phantom imaging further corroborates this evaluation. Figure 4B displays representative \(T_1\)-weighted MR images of GNP-Dex solutions at different concentrations (0.78–7.8 mg/mL) and the corresponding Mn\(^{2+}\) ion concentration (0.22–90.88 \(\mu M\)) for each dose. These concentrations correspond to the equilibrium plasma concentration in rodents (average weight = 200 g) if the GNP-Dex is injected at doses between 1 and 500 mg/kg. Also included as baseline controls are \(T_1\)-weighted images of DDI water and dextran solution. The images clearly show a substantial dose-dependent contrast enhancement compared with the baseline controls. The plasma concentration of the Gd\(^{3+}\) chelate-based CA at a clinical dose of 0.1 mmol/kg in a 200 g rat would be 1.5 mM, which is 17 times higher than the highest concentrations of Mn\(^{2+}\) (90.88 \(\mu M\)) in GNP-Dex solution (see Calculation of the plasma concentration for relaxivity in the Supplementary materials section). This suggests that GNP-Dex can provide similar MR contrast at lower dosages.

Table 5 compares the values of various physiochemical properties of the GNP-Dex formulation with other US FDA-approved MRI CAs.\(^{41–46}\) Most Gd\(^{3+}\) chelate-based clinical MRI CAs are hyper-osmolar, ranging in value from 630 to 1,970 mOsm/kg,\(^{41–46}\) while the Mn\(^{2+}\) chelate-based MRI CA Teslascan and iron oxide nanoparticle-based MRI CA Feridex are iso-osmolar.\(^1,6\) In the presence of mannitol, the GNP-Dex formulations were found to be iso-osmolar over a wide range of concentrations (0.1–100.0 mg/mL). The viscosity values of 1.3–4.4 cP for GNP-Dex formulations are within the range measured for blood and are similar to those of other MRI CAs. Comparison of the partition coefficient value of ~0.18 for the GNP-Dex formulation with those of clinically approved MRI CAs indicates that the GNP-Dex formulation could be less hydrophilic than Magnevist, ProHance\(^8\) (Bracco Diagnostics Inc., Princeton, NJ, USA), Omniscan\(^\text{TM}\), Teslascan, and OptiMark\(^\text{TM}\) (Mallinkrodt, Hazelwood, MO, USA), and more hydrophilic than MultiHance\(^8\) (Bracco Diagnostics Inc.). Most of the clinical MRI CAs show insignificant protein binding except for MultiHance and Teslascan. MultiHance shows less than 5% plasma protein binding.\(^42\)

In the case of Teslascan, the chelate fofidip does not bind to the protein; however, the Mn\(^{2+}\) ions, after dissociating from the chelate, show 27% protein binding in whole human blood in vitro.\(^44\) The GNP-Dex did not show significant protein binding. The \(r_1\) relaxivity for US FDA-approved Gd\(^{3+}\) and Mn\(^{2+}\) chelate-based MRI CAs is 2.2–4.5 mM\(^{-1}\)s\(^{-1}\); GNP-Dex has \(r_1\) relaxivity of 92 mM\(^{-1}\)s\(^{-1}\), which is 20- to 40-fold greater than those of Gd\(^{3+}\) and Mn\(^{2+}\) chelate-based MRI CAs.\(^8\)

The size of the GNP-Dex suggests that, similar to other macromolecular MRI CAs,\(^47\) the formulation will be retained in the intravascular compartment, thus may be suitable as a blood pool agent. Future in vivo preclinical MRI studies should provide insights into its potential application. Our previous relaxometric studies on GNPs indicate that multiple structural and molecular dynamic parameters that characterize the water molecule–MRI CA interactions, and
affect the $T_1$ relaxation mechanism, are modulated and are responsible for the observed increase in the relaxivity.\textsuperscript{48} The parameters include the number of water molecules ($q$) that can simultaneously coordinate with the Mn$^{2+}$ ions intercalated within the GNPs, the residence lifetime ($\tau_{q}$) of the water molecules coordinated on the Mn$^{2+}$ ions, and the rotational correlation time ($\tau_{c}$) of the GNPs.

Over the past 10 years, carbon nanostructures such as gadofullerenes (represented as Gd@C$_{60}$, Gd@C$_{82}$, and Gd@C$_{24}$) and gadonanotubes (represented as Gd@US-tubes, where “US-tubes” means “ultra-short single-walled carbon nanotubes”) that encapsulate Gd$^{3+}$ metal ions have been proposed as $T_1$ CAs for MRI.\textsuperscript{1,49} Even though these MRI CAs show higher relaxivity compared with clinical MRI CAs, none has translated into clinical use. Recent reports also show that administration of clinical Gd$^{3+}$-based MRI CAs (especially Omniscan) to patients with severe acute or chronic renal insufficiency (glomerular filtration rate $<30$ mL/min/1.73 m$^2$), significantly increases their risk for developing nephrogenic systemic fibrosis.\textsuperscript{5} As a result of these findings, the US FDA has restricted their use in patients suffering from renal insufficiency and instructed manufacturers to include mandatory box warnings and disclose contraindications for this high-risk group on the product labeling of all Gd$^{3+}$-based MRI CAs.\textsuperscript{5} Recently, manganese has received attention as a possible alternative to gadolinium. Manganese, a natural cellular constituent resembling Ca$^{2+}$, which often functions as a regulatory cofactor for enzymes and receptors, was one of first elements reported suitable as a CA for MRI.\textsuperscript{2} Manganese toxicity is rare, and has only been reported following long-term exposure to high concentrations, which has resulted in neurological symptoms.\textsuperscript{2} The two Mn$^{2+}$-based agents – Teslascan and an oral CA containing manganese (II) chloride (Bracco Diagnostics Inc.) – that were approved for clinical use have been discontinued. The synthesis and characterization of the highly water-soluble Mn$^{2+}$ ion intercalated GNP-Dex formulations, along with the positive results of their key in vitro physiochemical properties opens avenues for further in vitro and in vivo preclinical studies to assess their suitability as a next-generation $T_1$ MRI CA with a safety and efficacy profile that can overcome the outlined limitations.

**Conclusion**

The GNP-Dex formulation shows very high solubility (up to 100 mg/mL) and stability in deionized water and biological buffers. The osmolality of GNP-Dex is lower than that of blood, and can be adjusted to be similar to blood by adding the diuretic mannitol. The viscosities of the GNP-Dex formulations were within the range of blood viscosity. At physiological temperatures ($37^\circ$C), GNP-Dex was structurally stable and the intercalated Mn$^{2+}$ ions did not dissociate for up to 24 hours. Most of the GNP-Dex nanoparticles were hydrophilic, and a small fraction was amphiphilic. At potential therapeutic dosages, GNP-Dex showed very little or no interaction with blood protein HSA, suggesting that they prevent nonspecific adsorption of proteins. Moreover, the formulations did not trigger histamine release in whole human blood, suggesting that they are unlikely to evoke allergic responses. The high $r_1$ relaxivity ($92$ mM$^{-1}$s$^{-1}$) of GNP-Dex allowed significant contrast enhancement of $T_1$-weighted MRI phantoms even at modest (nM) concentrations of Mn$^{2+}$ ions. The in vitro results show that the physicochemical properties of the GNP-Dex were comparable to or better than those of clinically approved MRI CAs. The studies open avenues for further in vitro and in vivo preclinical studies to translate this promising $T_1$ MRI CA into clinical use.

**Acknowledgments**

This work was sponsored by the Wallace H Coulter Foundation. The authors thank Dr David Hirschberg for his help with performing ICP-MS and Ms Shelagh Zegers for her help with lyophilization.

**Disclosure**

The authors declare no conflicts of interest in this work.

**References**

1. Sitharaman B, Wilson LJ. Gadofullerenes and gadonanotubes: a new paradigm for high-performance magnetic resonance imaging contrast agent probes. *J Biomed Nanotechnol*. 2007;3(4):342–352.
2. Pan D, Caruthers SD, Senpan A, Schmieder AH, Wickline SA, Lanza GM. Revisiting an old friend: manganese-based MRI contrast agents. *Wiley Interdiscip Rev Nanomed Nanobiotechnol*. 2011;3(2):162–173.
3. Ananta JS, Godin B, Sethi R, et al. Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast. *Nat Nanotechnol*. 2010;5(11):815–821.
4. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium-based contrast agents: a summary of the medical literature reporting. *Eur J Radiol*. 2008;66(2):230–234.
5. Bayer HealthCare Pharmaceuticals Inc, Bracco Diagnostics Inc, GE Healthcare, Mallinkrodt Inc. Important Drug Warning for Gadolinium-based Contrast Agents [letter to healthcare professionals]. Bayer HealthCare Pharmaceuticals Inc, Bracco Diagnostics Inc, GE Healthcare, Mallinkrodt Inc; 2007. Available from: http://www.fda.gov/downloads/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm154532.pdf. Accessed June 18, 2013.
6. Feng L, Liu Z. Graphene in biomedicine: opportunities and challenges. *Nanomedicine (Lond)*. 2011;6(2):317–324.
7. Paratala BS, Jacobson BD, Kanakia S, Francis LD, Sitharaman B. Physicochemical characterization, and relaxometry studies of micrographite oxide, graphene nanoplatelets, and nanoribbons. *PLoS One*. 2012;7(6):e38185.
8. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40(11):715–724.

9. Vogler H, Platzek J, Schuhmann-Giampieri G, et al. Pre-clinical evaluation of gadobutrol: a new, neutral, extracellular contrast agent for magnetic resonance imaging. Eur J Radiol. 1995;21(1):1–10.

10. ICH. Safety pharmacology studies for human pharmaceuticals. Geneva: International Conference on Harmonisation; 2000. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/STADIcu6STAD1Guideline.pdf. Accessed July 15, 2013.

11. US FDA. Developing medical imaging drug and biological products part 1: conducting safety assessments. Rockville: US Food and Drug Administration; 2004. Available from: http://www.fda.gov/downloads/Drugs/…Guidances/ucm071600.pdf. Accessed July 15, 2013.

12. OECD. OECD guidelines for the testing of chemicals. Paris: Organisation for Economic Co-operation and Development; 2000. Available from: http://www.oecd.org/chemicalsafety/testing/2731134.pdf. Accessed July 15, 2013.

13. Runge VM. Safety of approved MR contrast media for intravenous injection. J Magn Reson Imaging. 2000;12(2):205–213.

14. Zhang S, Yang K, Feng L, Liu Z. In vitro and in vivo behaviors of dextran functionalized graphene. Carbon. 2011;49(12):4040–4049.

15. Sirlin CB, Vera DR, Corbeil JA, Caballero MB, Buxton RB, Matrey R. Gadolinium-DTPA-dextran: a macromolecular MR blood pool contrast agent. Acad Radiol. 2004;11(12):1361–1369.

16. Feridex IV (ferumoxides injectable solution) [package insert]. Wayne, NJ: Bayer Healthcare Pharmaceuticals Inc; 2007. Available from: http://www.amagpharma.com/documents/products/pdfs/feridex_insert.pdf. Accessed June 18, 2013.

17. Martwiset S, Koh AE, Chen W. Nonfoiling characteristics of dextran-containing surfaces. Langmuir. 2006;22(19):8192–8196.

18. Stankovich S, Dikin DA, Piner RD, et al. Synthesis of graphene-based nanosheets via chemical reduction of exfoliated graphite oxide. Carbon. 2007;45(7):1558–1565.

19. Tang M, Dou H, Sun K. One-step synthesis of water-soluble dextran functionalized graphene. Polymer. 2006;47(2):728–734.

20. Zate JL. Physical stability of suspensions. J Soc Cosmet Chem. 1985;36(6):393–411.

21. Tweedle MF. The ProHance story: the making of a novel MRI contrast agent. Eur Radiol. 1997;7 Suppl 2:225–230.

22. Hummers WS Jr, Offeman RE. Preparation of graphitic oxide. J Am Chem Soc. 1958;80(6):1339.

23. Shan C, Yang H, Han D, Zhang Q, Ivaska A, Niu L. Water-soluble graphene covalently functionalized by biocompatible poly-L-lysine. Langmuir. 2009;25(20):12030–12033.

24. Liu Z, Robinson JT, Sun X, Dai H. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. J Am Chem Soc. 2008;130(33):10876–10877.

25. Kim YK, Kim MH, Min DH. Biocompatible reduced graphene oxide prepared by using dextran as a multifunctional reducing agent. Chem Commun (Camb). 2011;47(11):3195–3197.

26. Deray G, Jacobs C. Are low osmolality contrast media less nephrotoxic? Nephrol Dial Transplant. 1996;11(6):930–931.

27. American Society of Health-System Pharmacists. Quick Guide to Contrast Media. Bethesda, MD: Contrast Media and Medication Management Standard Resource Center; 2010.

28. Pugh ND. Haemodynamic and rheological effects of contrast media: the role of viscosity and osmolality. Eur Radiol. 1996;6 Suppl 2: S13–S15.

29. Voelz MD, Nelson MA, McDaniel MC, Manoukian SV. The important properties of contrast media: focus on viscosity. J Invasive Cardiol. 2007;19(3):1A–9A.

30. Lancelot E, Idée JM, Laclédère C, Santus R, Corot C. Effects of two dimeric iodinated contrast media on renal medullary blood perfusion and oxygenation in dogs. Invest Radiol. 2002;37(7):368–375.

31. Caravan P. Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action. Acc Chem Res. 2009;42(7):851–862.

32. van Liempd S, Morrison D, Sysmans L, Nelis P, Mortishire-Smith R. Development and validation of a higher-throughput equilibrium dialysis assay for plasma protein binding. J Lab Autom. 2011;16(1):56–67.

33. Rimkus G, Bremer-Streek S, Grütter C, Kaiser WA, Hilger I. Can we accurately quantify nanoparticle associated proteins when constructing high-affinity MRI molecular imaging probes? Contrast Media Mol Imaging. 2011;6(3):119–125.

34. Watts DL. The nutritional relationships of manganese. J Orthomol Med. 1990;5(4):219–222.

35. Sullivan JF, Blotcky AJ, Jeton MM, Hahn HK, Burch RE. Serum levels of selenium, calcium, copper magnesium, manganese and zinc in various human diseases. J Nutr. 1998(1):1432–1437.

36. Aschner M, Aschner JL. Manganese neurotoxicity: cellular effects and blood-brain barrier transport. Neurosci Biobehav Rev. 1991;15(3):333–340.

37. Marcos SK, Thomsen HS, Webb JA; Contrast Media Safety Committee of the European Society of Urogenital Radiology (ESUR). Dialysis and contrast media. Eur Radiol. 2002;12(12):3026–3030.

38. Prince MR, Zhang H, Zou Z, Staron RB, Brill PW. Incidence of in-hospital nephrogenic systemic fibrosis among gadolinium contrast media reactions. AJR Am J Roentgenol. 2011;196(2):W138–W143.

39. Dillman JR, Ellis JJ, Cohan RH, Stroose PJ, Jan SC. Allergic-like breakthrough reactions to gadolinium contrast agents after corticosteroid and antihistamine premedication. AJR Am J Roentgenol. 2008;190(1):187–190.

40. Kuefner MA, Feurle J, Uder M, Bautz W, Schwellberger H. Influence of magnetic resonance contrast media on the activity of histamine inactivating enzymes. Acad Radiol. 2009;16(3):358–362.

41. ProHance® (gadoteridol) injection, solution [product label]. Princeton, NJ: Bracco Diagnostics Inc; nd. Available from: http://www.fda.gov/downloads/Drugs/…Guidances/ucm071600.pdf. Accessed June 18, 2013.

42. MultiHance – gadobenate dimeglumine injection, solution [highlights of prescribing information]. Princeton, NJ: Bracco Diagnostics Inc; nd. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ucm071600.pdf. Accessed June 18, 2013.

43. Magnevist® (brand of gadopentetate dimeglumine) [package insert]. Wayne, NJ: Bayer Healthcare Pharmaceuticals Inc; 2011. Available from: http://www.magnevist.com/products/contrast-media/products/Magnevist_PI.pdf. Accessed June 18, 2013.

44. Teslascan data sheet [webpage on the Internet]. Portland: RxList Inc.; 2009. Available from: http://www.rxlist.com/teslascan-drug.htm. Accessed July 15, 2013.

45. Optimark [package insert]. Hazlewood, MO: Mallinckrodt; nd. Available from: http://www.mallinckrodt.com/webforms/threecolumn.aspx?id=947. Accessed June 18, 2013.

46. Omniscan™ (gadodiamide) injection [product label]. Princeton, NJ: GE Healthcare; 2011. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ucm071600.pdf. Accessed June 18, 2013.

47. Kobayashi H, Brechbiel MW. Dendrimer-based macromolecular MRI contrast agents: characteristics and application. Mol Imaging. 2003;2(1):1–10.

48. Yang K, Hu L, Ma X, et al. Multimodal imaging guided photothermal therapy using functionalized graphene nanosheets anchored with magnetic nanoparticles. Adv Mater. 2012;24(14):1868–1872.

49. Sitharaman B, Wilson LJ. Gadonanotubes as new high-performance contrast media. Adv Drug Deliv Rev. 2003;55(6):705–718.
Supplementary materials
Calculation of the dose
If the concentration of the MRI CA solution is 1 mg/mL, and it is required to be intravenously administered at a dose of 100 mg/kg in a 200 g rat, the CA injection volume (v) is calculated as follows:
\[ v (mL) \times 1 \text{ mg/mL} = 100 \text{ mg/kg} \times 200 \text{ g} \]
\[ v (mL) \times 1 \text{ mg/mL} = (100 \text{ mg/1,000 g}) \times 200 \text{ g} \]
\[ v (mL) \times 1 \text{ mg/mL} = 20 \text{ mg} \]
\[ v (mL) = 20 \text{ mg/1 mg/mL} \]
\[ v (mL) = 20 \text{ mL} \]

The total circulating blood volume in a 200 g rat has been assumed to be \( \sim 12.8 \text{ mL} \). Therefore, the injected volume percent (\( \% \)) (P) is calculated as:
\[ P \% = \frac{20 \text{ mL} \times 12.8 \text{ mL}}{100 \%} \]
\[ P \% = 156.25\% \]

Similarly, if the concentration of the MRI CA solution is 1 mg/mL, and it is required to be intravenously administered at a dose of 1 mg/kg in a 200 g rat, the CA injection volume (v) is calculated as:
\[ v (mL) \times 1 \text{ mg/mL} = 1 \text{ mg/kg} \times 200 \text{ g} \]
\[ v (mL) \times 1 \text{ mg/mL} = (1 \text{ mg/1,000 g}) \times 200 \text{ g} \]
\[ v (mL) = 2 \text{ mg} \]
\[ v (mL) = 2 \text{ mL} \]

The injected volume percent (\( \% \)) (P) can be calculated as:
\[ 12.8 \text{ mL} \times P \% = 2 \text{ mL} \times 100\% \]
\[ P \% = (2 \text{ mL/12.8 mL}) \times 100\% \]
\[ P \% = 1.56\% \]

In humans, the total circulating blood volume in a 70 kg adult human is 5 L. Therefore, if the concentration of the MRI CA solution is 1 mg/mL, and a 100 mg/kg dose has to be administered in a 70 kg human, the injection volume (v) of CA can be calculated as:
\[ v (mL) \times 1 \text{ mg/mL} = 100 \text{ mg/kg} \times 70,000 \text{ g} \]
\[ v (mL) \times 1 \text{ mg/mL} = (100 \text{ mg/1,000 g}) \times 70,000 \text{ g} \]
\[ v (mL) = 7,000 \text{ mg/1 mg/mL} \]
\[ v (mL) = 7,000 \text{ mL} \]

The injected volume percent (\( \% \)) (P) can be calculated as:
\[ 5,000 \text{ mL} \times P \% = 7,000 \text{ mL} \times 100\% \]
\[ P \% = (7,000 \text{ mL/5,000 mL}) \times 100\% \]
\[ P \% = 140\% \]

Similarly, if the concentration of the MRI CA solution is 1 mg/mL, and it is required to be intravenously administered at a dose of 1 mg/kg in a 70 kg human, the CA injection volume (v) is calculated as:
\[ v (mL) \times 1 \text{ mg/mL} = 1 \text{ mg/kg} \times 70,000 \text{ g} \]
\[ v (mL) \times 1 \text{ mg/mL} = (1 \text{ mg/1,000 g}) \times 70,000 \text{ g} \]
\[ v (mL) \times 1 \text{ mg/mL} = 7 \text{ mg} \]
\[ v (mL) = 7 \text{ mg/1 mg/mL} \]
\[ v (mL) = 7 \text{ mL} \]

The injected volume percent (\( \% \)) (P) can be calculated as:
\[ 5,000 \text{ mL} \times P \% = 7 \text{ mL} \times 100\% \]
\[ P \% = (7 \text{ mL}/5,000 \text{ mL}) \times 100\% \]
\[ P \% = 1.4\% \]

If the concentration of the MRI CA solution is 100 mg/mL, and it is required to be intravenously administered at a dose of 500 mg/kg in a 200 g rat, the CA injection volume (v) is calculated as:
\[ v (mL) \times 100 \text{ mg/mL} = 500 \text{ mg/kg} \times 200 \text{ g} \]
\[ v (mL) \times 100 \text{ mg/mL} = (500 \text{ mg/1,000 g}) \times 200 \text{ g} \]
\[ v (mL) \times 100 \text{ mg/mL} = 100 \text{ mg} \]
\[ v (mL) = 100 \text{ mg/100 mg/mL} \]
\[ v (mL) = 1 \text{ mL} \]

The total circulating blood volume in a 200 g rat has been assumed to be \( \sim 12.8 \text{ mL} \).

Thus, the injected volume percent (\( \% \)) (P) can be calculated as:
\[ 12.8 \text{ mL} \times P \% = 1 \text{ mL} \times 100\% \]
\[ P \% = (1 \text{ mL/12.8 mL}) \times 100\% \]
\[ P \% = 7.8\% \]

Calculation of the plasma concentration for relaxivity
At a 0.1 mmol/kg clinical dose, the total amount of MRI CA that will be injected in a 200 g rat will be 0.1 mmol/kg × 0.2 kg = 0.02 mmol.

With a total circulating blood volume of \( \sim 12.8 \text{ mL} \), the plasma concentration of Gd\(^{3+}\) CA can be calculated as:
\[ 0.02 \text{ mmol/12.8 mL} = 0.001562 \text{ mmol/mL} = 1.562 \mu \text{M} \]

As determined by ICP-MS, the Mn\(^{2+}\) in GNP-Dex by weight is 0.064%. Therefore, the weight (z) (mg) of Mn\(^{2+}\) ions in 1 mL of 7.8 mg/mL solution of GNP-Dex can be calculated as:
\[ 100 \text{ mg} \times z \text{ (mg)} = 7.8 \text{ mg} \times 0.064 \text{ mg} \]
\[ z \text{ (mg)} = (7.8 \text{ mg/100 mg}) \times 0.064 \text{ mg} \]
\[ z \text{ (mg)} = 0.005 \text{ mg} \]

Converting mass of Mn\(^{2+}\) into moles (molecular weight [MW] of Mn\(^{2+}\) 54.93):
\[ 0.5 \text{ mg} = (0.005 \times 10^{-3} \text{ g/54.93 g/mole}) = 9.08 \times 10^{-8} \text{ moles} \]

Thus, 7.8 mg/mL GNP-Dex solution has 9.08 \times 10^{-8} moles/mL or 90.80 \mu M of Mn\(^{2+}\) ions. This value is 17 times lower than the plasma concentration of Gd\(^{3+}\) chelate-based CA (1,562 \mu M) at clinical dose.
Table S1 Concentration of unbound protein measured by ultraviolet–visible (UV-Vis) spectrophotometry at equilibrium

| Concentration of GNP-Dex (mg/mL) | Concentration of unbound protein in protein compartment (mg/mL) | Concentration of unbound protein in GNP-Dex compartment (mg/mL) |
|----------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| 0.1                              | 0.03                                                          | 0.03                                                          |
| 1.0                              | 0.55                                                          | 0.07                                                          |
| 10.0                             | 5.44                                                          | 0.53                                                          |

Notes: In the equilibrium dialysis method, at equilibrium, if no protein is bound to the material of interest, the distribution of unbound (free) protein needed to be equal (ie, 0.025, 0.250, and 2.500 mg/mL of human serum albumin [HSA] in each compartment for 0.1, 1.0, and 10.0 mg/mL initial concentrations of HSA, respectively) at the end of equilibrium in both HSA and graphene nanoplatelets intercalated with manganese (Mn$^{2+}$) ions, functionalized with dextran (GNP-Dex) solution compartments. If the protein was binding to the GNP-Dex, the remaining unbound protein had to be distributed equally in both compartments. At equilibrium, 400 µL solutions were retrieved (initial volume 500 µL) from both compartments and were used to measure unbound protein concentration. The concentration of unbound HSA at the end of 24 hours’ incubation with the nanoparticles, as measured by UV-Vis spectrophotometry at 562 nm, did not decrease, which implies that no protein was bound to GNP-Dex.

Table S2 Concentration of released Mn$^{2+}$ ions in graphene nanoplatelets intercalated with manganese (Mn$^{2+}$) ions, functionalized with dextran (GNP-Dex) solutions at 37°C measured by ultraviolet–visible (UV-Vis) spectrophotometry to determine thermal stability

| Sample             | Mn$^{2+}$ concentration (µM) |
|--------------------|------------------------------|
| GNP-Dex 20 mg/mL   | <LOD (0.01)                  |
| GNP-Dex 50 mg/mL   | <LOD (0.01)                  |
| GNP-Dex 100 mg/mL  | <LOD (0.01)                  |

Notes: There was no color change observed by sodium bismuthate (NaBiO$_3$) test in GNP-Dex solutions at 3 and 24 hours. The Mn$^{2+}$ concentration measured by UV-Vis spectrophotometry was less than limit of detection (LOD).

Table S3 Concentration of released histamine in whole human blood in vitro measured after overnight incubation with graphene nanoplatelets intercalated with manganese (Mn$^{2+}$) ions, functionalized with dextran (GNP-Dex)

| Concentration of GNP-Dex (mg/mL) | Released histamine (ng/mL) |
|----------------------------------|----------------------------|
| Control                          | 19.8                       |
| 10.0                             | 8.80                       |
| 1.0                              | 5.59                       |
| 0.1                              | 5.59                       |

Notes: The histamine concentration in GNP-Dex was found to be lower than in the control (not treated with GNP-Dex), which suggests that GNP-Dex do not trigger histamine release.